Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Language: French

Language: French

CHU Bordeaux Haut-Leveque (Site 2534)

September 8, 2023

By

CENTRE LEON BERARD-Medical oncology (Site 0703)

August 25, 2023

By

Centre Hospitalier Régional Universitaire de Tours – Hôpital Bretonneau (Site 2602)

August 25, 2023

By

Pitie Salpetriere University Hospital (Site 1102)

August 18, 2023

By

Centre Hospitalier de Cornouaille Quimper – Concarneau (Site 2600)

August 18, 2023

By

centre hospitalier lyon sud (Site 3606)

August 4, 2023

By

Institut Universitaire du Cancer Toulouse – Oncopole – CHU de TOULOUSE (Site 0706)

July 21, 2023

By

Hopitaux Universitaires Paris Centre-Hopital Cochin (Site 2603)

July 14, 2023

By

Institut de Cancérologie de Lorraine Alexis Vautrin (Site 2532)

June 23, 2023

By

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma

June 20, 2023

By Tyler Kalist

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility